Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation

  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
  • Vargas Padilla, María Victoria
  • Lobo Selma, Laura
  • Chacón-Barrado, Antonio
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings., E.d.Á. laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to E.d.Á., Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to E.d.Á., ECAEC222952DEAL, Fundación Científica AECC to E.d.Á, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to F.O. Fundación Domingo Martínez to F.O. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to D.D.-B. Fundación Getthi ONC18PE01/2022 to E.d.Á., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.